Literature DB >> 23642101

Utility of geriatric assessment to predict mortality in the oldest old: the Octabaix study 3-year follow-up.

Francesc Formiga1, Assumpta Ferrer, David Chivite, Abelardo Montero, Hector Sanz, Ramón Pujol.   

Abstract

OBJECTIVE: Few studies have prospectively evaluated the utility of geriatric assessment tools as predictors of mortality in the oldest population. We investigated predictors of death in an oldest-old cohort after 3 years of follow-up.
METHODS: The Octabaix study is a prospective, community-based study with a follow-up period of 3 years involving 328 subjects aged 85 at baseline. Data were collected on functional and cognitive status, co-morbidity, nutritional and falls risk, quality of life, social risk, and long-term drug prescription. Vital status for the total cohort was evaluated after 3 years of follow-up.
RESULTS: Mortality after 3 years was 17.3%. Patients who did not survive had significantly poorer baseline functional status for basic and instrumental activities of daily living (Barthel and Lawton Index), higher co-morbidity (Charlson), higher nutritional risk (Mini Nutritional Assessment), higher risk of falls (Tinetti Gait Scale), poor quality of life (visual analog scale of the Quality of Life Test), and higher number of chronic drugs prescribed. Cox regression analysis identified the Lawton Index (hazard ratio [HR] 0.82, 95% confidence interval [CI] 0.73-0.89) and the number of chronic drugs prescribed (HR 1.09, 95% CI 1.01-1.18) as independent predictors of mortality at 3 years.
CONCLUSIONS: Among the variables studied, the ability to perform instrumental activities of daily living and using few drugs on a chronic basis at baseline are the best predictors of which oldest-old community-dwelling subjects survive after a 3-year follow-up period.

Entities:  

Mesh:

Year:  2013        PMID: 23642101     DOI: 10.1089/rej.2013.1422

Source DB:  PubMed          Journal:  Rejuvenation Res        ISSN: 1549-1684            Impact factor:   4.663


  7 in total

1.  Inverted CD4:CD8 ratio is not associated with three-year mortality in a sample of community-dwelling oldest old: the OCTABAIX immune study.

Authors:  F Formiga; A Ferrer; G Padros; A Cintra; R Pujol
Journal:  J Nutr Health Aging       Date:  2014-04       Impact factor: 4.075

2.  Free thyroxine but not TSH levels are associated with decline in functional status in a cohort of geriatric outpatients.

Authors:  Aline S da S Correia; Michele L F Nascimento; Letícia B B de M Teixeira; Silvana O E Silva; Mário Vaisman; Patricia F S Teixeira
Journal:  Eur Geriatr Med       Date:  2021-11-24       Impact factor: 1.710

Review 3.  Is Technology Present in Frailty? Technology a Back-up Tool for Dealing with Frailty in the Elderly: A Systematic Review.

Authors:  Iranzu Mugueta-Aguinaga; Begonya Garcia-Zapirain
Journal:  Aging Dis       Date:  2017-04-01       Impact factor: 6.745

4.  Systematic review on the instruments used for measuring the association of the level of multimorbidity and clinically important outcomes.

Authors:  Eng Sing Lee; Hui Li Koh; Elaine Qiao-Ying Ho; Sok Huang Teo; Fang Yan Wong; Bridget L Ryan; Martin Fortin; Moira Stewart
Journal:  BMJ Open       Date:  2021-05-05       Impact factor: 2.692

5.  Is polypharmacy associated with mortality in the very old: Findings from the Newcastle 85+ Study.

Authors:  Laurie E Davies; Andrew Kingston; Adam Todd; Barbara Hanratty
Journal:  Br J Clin Pharmacol       Date:  2022-01-27       Impact factor: 3.716

6.  Evidence of functional declining and global comorbidity measured at baseline proved to be the strongest predictors for long-term death in elderly community residents aged 85 years: a 5-year follow-up evaluation, the OCTABAIX study.

Authors:  Francesc Formiga; Assumpta Ferrer; Gloria Padros; Abelardo Montero; Carme Gimenez-Argente; Xavier Corbella
Journal:  Clin Interv Aging       Date:  2016-04-18       Impact factor: 4.458

7.  [Diabetes mellitus at 85 years in the community. Octabaix study].

Authors:  Assumpta Ferrer; Francesc Formiga; Glòria Padrós; Teresa Badia
Journal:  Aten Primaria       Date:  2014-09-10       Impact factor: 1.137

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.